Adding bevacizumab to standard treatment for new glioblastoma does not extend life
In short: A randomized, double-blind trial of 637 adults with newly diagnosed glioblastoma found that adding the drug bevacizumab to standard chemotherapy and radiotherapy did not improve overall survival. While patients receiving the drug lived slightly longer without their disease progressing, they also experienced a higher burden of side effects.
The study aimed to see if targeting vascular growth factors could help patients who typically receive temozolomide and radiation. Although bevacizumab prolonged progression-free survival compared to a placebo, it failed to meet the researchers' primary goal of extending life expectancy.
Participants in the bevacizumab group reported more frequent issues with hypertension, neutropenia, and declining neurocognitive function. A key limitation is that this was an observational comparison of outcomes where the drug did not reach its pre-specified target for survival improvement.
Why it matters: This research highlights that some drugs can slow disease progression without actually extending a patient's life.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Research: Gilbert et al. (2014). A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma. New England Journal of Medicine.
To cite this card, link to https://intellectplus.co.uk/app/science-research-adding-bevacizumab-to-standard-treatment-for-new-glioblastom.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Science · Latest · A–Z · All topics